Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402): Final report

被引：1
|
作者：
Kishimoto, T.
Imamura, H.
Uedou, F.
Fujitani, K.
Iijima, S.
Takiuchi, H.
Imano, M.
Shimokawa, T.
Kurokawa, Y.
Furukawa, H.
机构：
[1] Sakai Municipal Hosp, Sakai, Osaka, Japan
[2] Osaka Med Ctr Canc & Cardiovasc Dis, Osaka, Japan
[3] Natl Osaka Med Ctr, Osaka, Japan
[4] Minoh City Hosp, Mino, Japan
[5] Osaka Med Coll Hosp, Osaka, Japan
[6] Kinki Univ, Osaka, Japan
[7] Yamanashi Univ, Kofu, Yamanashi 400, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.4015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4015
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer
    Mizuno, Nobumasa
    Yamao, Kenji
    Komatsu, Yoshito
    Munakata, Masaki
    Ishiguro, Atsushi
    Yamaguchi, Taketo
    Ohkawa, Shinichi
    Kida, Mitsuhiro
    Ioka, Tatsuya
    Takeda, Koji
    Kudo, Toshihiro
    Kitano, Masayuki
    Iguchi, Haruo
    Tsuji, Akihito
    Ito, Tetsuhide
    Tanaka, Masao
    Furuse, Junji
    Hamada, Chikuma
    Sakata, Yuh
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [22] Phase II Study of S-1 Monotherapy as a First-line, Combination Therapy of S-1 plus Cisplatin as a Second-line, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma Phase II Study of S-1, S-1 plus Cisplatin, and Weekly Paclitaxel in Patients with Advanced Gastric Carcinoma
    Rino, Yasushi
    Yukawa, Norio
    Wada, Nobuyuki
    Suzuki, Makoto
    Murakami, Hitoshi
    Yamada, Takanobu
    Nakayama, Hirotaka
    Yamamoto, Naoto
    Sato, Tsutomu
    Yamada, Roppei
    Ohshima, Takashi
    Masuda, Munetaka
    Imada, Toshio
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2008, 2 : 375 - 383
  • [23] Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study
    Abudureheiyimu, Nilupai
    Wu, Yun
    Li, Qing
    Zhang, Pin
    Ma, Fei
    Yuan, Peng
    Luo, Yang
    Fan, Ying
    Chen, Shanshan
    Cai, Ruigang
    Li, Qiao
    Han, Yiqun
    Xu, Hangcheng
    Wang, Yan
    Wang, Jiayu
    JOURNAL OF THE NATIONAL CANCER CENTER, 2023, 3 (02): : 115 - 120
  • [24] A randomized phase II trial of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment versus SP randomized PII trial (XParTS II).
    Kobayashi, Michiya
    Tsuburaya, Akira
    Nishikawa, Kazuhiro
    Kawada, Junji
    Namikawa, Tsutomu
    Fukushima, Ryoji
    Kojima, Hiroshi
    Tanabe, Kazuaki
    Yamaguchi, Kazuya
    Yoshino, Shigefumi
    Takahashi, Masazumi x
    Hirabayashi, Naoki
    Sato, Seiji
    Nemoto, Hiroshi
    Rino, Yasushi
    Yoshikawa, Takaki
    Nakajima, Junta
    Morita, Satoshi
    Sakamoto, Junichi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [25] Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701
    Kawase, Tomono
    Imamura, Hiroshi
    Goto, Masahiro
    Kimura, Yutaka
    Ueda, Shugo
    Matsuyama, Jin
    Nishikawa, Kazuhiro
    Sugimoto, Naotoshi
    Fujita, Junya
    Tamura, Takao
    Fukushima, Norimasa
    Kawakami, Hisato
    Sakai, Daisuke
    Kurokawa, Yukinori
    Shimokawa, Toshio
    Satoh, Taroh
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (10) : 1871 - 1880
  • [26] Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701
    Tomono Kawase
    Hiroshi Imamura
    Masahiro Goto
    Yutaka Kimura
    Shugo Ueda
    Jin Matsuyama
    Kazuhiro Nishikawa
    Naotoshi Sugimoto
    Junya Fujita
    Takao Tamura
    Norimasa Fukushima
    Hisato Kawakami
    Daisuke Sakai
    Yukinori Kurokawa
    Toshio Shimokawa
    Taroh Satoh
    International Journal of Clinical Oncology, 2021, 26 : 1871 - 1880
  • [27] Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial
    Wen Zhang
    Chunxia Du
    Yongkun Sun
    Lin Yang
    Chengxu Cui
    Zhichao Jiang
    Chengfeng Wang
    Jinwang Wang
    Aiping Zhou
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 655 - 660
  • [28] Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial
    Zhang, Wen
    Du, Chunxia
    Sun, Yongkun
    Yang, Lin
    Cui, Chengxu
    Jiang, Zhichao
    Wang, Chengfeng
    Wang, Jinwang
    Zhou, Aiping
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (04) : 655 - 660
  • [29] S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial
    Kang, Yoon-Koo
    Chin, Keisho
    Chung, Hyun Cheol
    Kadowaki, Shigenori
    Oh, Sang Cheul
    Nakayama, Norisuke
    Lee, Keun-Wook
    Hara, Hiroki
    Chung, Ik-Joo
    Tsuda, Masahiro
    Park, Se Hoon
    Hosaka, Hisashi
    Hironaka, Shuichi
    Miyata, Yoshinori
    Ryu, Min-Hee
    Baba, Hideo
    Hyodo, Ichinosuke
    Bang, Yung-Jue
    Boku, Narikazu
    LANCET ONCOLOGY, 2020, 21 (08): : 1045 - 1056
  • [30] Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05)
    Tanabe, K.
    Fujii, M.
    Nishikawa, K.
    Kunisaki, C.
    Tsuji, A.
    Matsuhashi, N.
    Takagane, A.
    Ohno, T.
    Kawase, T.
    Kochi, M.
    Yoshida, K.
    Kakeji, Y.
    Ichikawa, W.
    Chin, K.
    Terashima, M.
    Takeuchi, M.
    Nakajima, T.
    ANNALS OF ONCOLOGY, 2015, 26 (09) : 1916 - 1922
12345